StockNews.com Begins Coverage on Catalent (NYSE:CTLT)

Investment analysts at StockNews.com assumed coverage on shares of Catalent (NYSE:CTLT) in a report issued on Monday. The brokerage set a “hold” rating on the stock.

CTLT has been the subject of a number of other research reports. Baird R W downgraded shares of Catalent from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. Robert W. Baird reiterated a “neutral” rating and issued a $63.50 price objective on shares of Catalent in a research note on Tuesday, September 24th. Eight analysts have rated the stock with a hold rating, According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $63.40.

Catalent Stock Performance

Shares of NYSE CTLT opened at $63.48 on Monday. The company’s 50 day simple moving average is $62.16 and its 200 day simple moving average is $60.42. Catalent has a fifty-two week low of $41.15 and a fifty-two week high of $63.50. The firm has a market capitalization of $11.52 billion, a P/E ratio of -28.09, a P/E/G ratio of 2.69 and a beta of 1.15. The company has a debt-to-equity ratio of 1.38, a current ratio of 2.51 and a quick ratio of 1.96.

Catalent (NYSE:CTLT) last posted its earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.18). Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The firm had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.06 billion. During the same quarter last year, the business posted ($0.10) earnings per share. The company’s revenue for the quarter was up 4.2% on a year-over-year basis. On average, analysts predict that Catalent will post 0.78 EPS for the current year.

Insider Activity at Catalent

In other news, Director Michelle R. Ryan sold 2,800 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $59.70, for a total value of $167,160.00. Following the sale, the director now owns 10,835 shares of the company’s stock, valued at $646,849.50. The trade was a 20.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.31% of the stock is owned by insiders.

Hedge Funds Weigh In On Catalent

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Athos Capital Ltd bought a new position in Catalent in the 3rd quarter worth $6,009,000. Oddo BHF Asset Management Sas purchased a new stake in shares of Catalent during the 3rd quarter valued at about $8,480,000. State Street Corp boosted its holdings in shares of Catalent by 1.5% during the 3rd quarter. State Street Corp now owns 7,451,135 shares of the company’s stock valued at $451,315,000 after acquiring an additional 113,095 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new position in shares of Catalent in the 3rd quarter worth approximately $1,131,000. Finally, Sumitomo Mitsui Trust Group Inc. lifted its stake in shares of Catalent by 3.7% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 405,318 shares of the company’s stock worth $24,550,000 after purchasing an additional 14,373 shares during the period.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.